Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

NAION is the second most frequent cause of vision loss due to optic nerve damage, with advanced age and long-standing type 2 ...

Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased ...

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased risk of nonarteritic anterior ischemic optic neuropathy. There was ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic, ...

The lawsuit said about four months later, Engel was diagnosed with nonarteritic anterior ischemic optic neuropathy, a condition in which a loss of blood flow to the optic nerve causes sudden and ...

At the 2-year, 3-year, and 4-year time points from the index date, those taking semaglutide had an increased risk for nonarteritic anterior ischemic optic neuropathy. HealthDay News — For patients ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date.

Recent research indicates that semaglutide, a medication often prescribed for diabetes management, may be associated with an elevated risk of developing nonarteritic anterior ischemic optic neuropathy ...